Charles Schwab Investment Management Inc Clearside Biomedical, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 20,216 shares of CLSD stock, worth $19,205. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,216
Previous 20,216
-0.0%
Holding current value
$19,205
Previous $26,000
3.85%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.7 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.09 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.84 Million0.04% of portfolio
-
Black Rock Inc. New York, NY798KShares$758,2300.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$707,6440.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $57.2M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...